Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference

Thursday, June 19, 2008 General News J E 4
PT. RICHMOND, Calif., June 18 Transcept Pharmaceuticals,Inc. today announced that Glenn A. Oclassen, President & Chief ExecutiveOfficer, will present at the Jefferies 2nd Annual Healthcare Conference in NewYork City on Wednesday, June 25, 2008 at 9:30 AM Eastern Time.

The presentation will be available as a webcast at

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical companyderiving significant new patient benefits from proven CNS drugs. Transceptdevelopment projects leverage new understanding of CNS conditions to provideadditional uses and enhanced clinical benefits for existing active agents. Thelead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublinguallozenge), is a low dose formulation of zolpidem for the treatment of insomniain patients who awaken in the middle of the night and have difficultyreturning to sleep. Phase 3 clinical trials have been completed forIntermezzo(R) and Transcept plans to submit an NDA in the third quarter of2008. Transcept is also developing TO-2060, a novel, fixed-dose combination ofolanzapine and ondansetron for the treatment of dopamine associatedpsychiatric disorders. For further information, please visit the company'swebsite at: Transcept Pharmaceuticals, Inc. The Ruth Group Michael Gill Investors/Media Director of Communications Stephanie Carrington/Jason Rando (510) 215-3575 (646) 536-7017 / 7025

SOURCE Transcept Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Rosetta Genomics Announces Three New Diagnostic Te...
William P. Sheridan Appointed Chief Medical Office...